receptor agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
=== Nationalist Congress Party === Vaghela joined the Nationalist Congress Party (NCP) in January 2019. He was appointed the National General Secretary as well as the State President of the party. He was removed from the post of State President in early June 2020, a week before 2020 Indian Rajya Sabha elections. He resigned from the NCP on 22 June 2020 citing his displeasure at his removal from the post and cross voting by NCP's only MLA Kandhal Jadeja in Rajya Sabha election.
Drugs are also used to inhibit enzymes needed for the survival of pathogens. For example, bacteria are surrounded by a thick cell wall made of a net-like polymer called peptidoglycan. Many antibiotics such as penicillin and vancomycin inhibit the enzymes that produce and then cross-link the strands of this polymer together. This causes the cell wall to lose strength and the bacteria to burst. In the figure, a molecule of penicillin (shown in a ball-and-stick form) is shown bound to its target, the transpeptidase from the bacteria Streptomyces R61 (the protein is shown as a ribbon diagram). Antibiotic drug design is facilitated when an enzyme that is essential to the pathogen's survival is absent or very different in humans. Humans do not make peptidoglycan, therefore antibiotics that inhibit this process are selectively toxic to bacteria. Selective toxicity is also produced in antibiotics by exploiting differences in the structure of the ribosomes in bacteria, or how they make fatty acids.
Smoking tobacco has serious negative effects on human health. Tobacco smoking is the greatest cause of preventable death globally. Half of tobacco smokers die from complications related to smoking. Active smokers are estimated to die an average of 10 years earlier than non-smokers. The World Health Organization estimates that, annually, more than 7 million people die from tobacco-related causes, including 1.6 million non-smokers due to passive smoking. It is further estimated to have caused 100 million deaths in the 20th century. Tobacco smoke contains over 70 chemicals, known as carcinogens, that cause cancer. It also contains nicotine, a highly addictive psychoactive drug. When tobacco is smoked, the nicotine causes physical and psychological dependency. Cigarettes sold in least developed countries have higher tar content and are less likely to be filtered, increasing vulnerability to tobacco smoking–related diseases in these regions. Tobacco use most commonly leads to diseases affecting the heart, liver, and lungs. Smoking is a major risk factor for several conditions, namely pneumonia, heart attacks, strokes, chronic obstructive pulmonary disease (COPD)—including emphysema and chronic bronchitis—and multiple cancers (particularly lung cancer, cancers of the larynx and mouth, bladder cancer, and pancreatic cancer). It is also responsible for peripheral arterial disease and high blood pressure. The effects vary depending on how frequently and for how many years a person smokes.
Sources: en.wikipedia.org
Variable pathlength absorption spectroscopy uses a determined slope to calculate concentration. As stated above this is a product of the molar absorptivity and the concentration. Since the actual absorbance value is taken at many data points at equal intervals, background subtraction is generally unnecessary. The image on the right is a linear plot showing both the background corrected data and the raw data. This shows that the absorbance values on the plot are offset by an equal amount and the slope of the two plots are equal. Thus, the concentration calculated from the two plots is equal. Other scalar components that contribute to the absorbance of a given sample like contaminants on the cuvette or a different cuvette material also are averaged out during the slope measurement. The technique is also applicable for in line measurements for TFF and chromatography applications.
Strassman argues that the more positive of the "external entities" encountered in DMT experiences should be understood as analogous to certain forms of angels: The medieval Jewish philosophers whom I rely upon for understanding the Hebrew Bible text and its concept of prophecy portray angels as God's intermediaries. That is, they perform a certain function for God. Within the context of my DMT research, I believe that the beings that volunteers see could be conceived of as angelic – that is, previously invisible, incorporeal spiritual forces that are engarbed or enclothed in a particular form – determined by the psychological and spiritual development of the volunteers – bringing a particular message or experience to that volunteer. Strassman's experimental participants also note that some other entities can subjectively resemble creatures more like insects and aliens. As a result, Strassman writes these experiences among his experimental participants "also left me feeling confused and concerned about where the spirit molecule was leading us. It was at this point that I began to wonder if I was getting in over my head with this research." Hallucinations of strange creatures had been reported by Stephen Szára in a 1958 study in psychotic patients, in which he described how one of his subjects under the influence of DMT had experienced "strange creatures, dwarves or something" at the beginning of a DMT trip.
21 July The Bodyhunters, about the disappearance of Royal Marine Alan Addis; on 8 August 1980, Royal Marine went missing in North Arm; the Forensic Search Advisory Group, from the Home Office, was founded in 1988 by forensic archaeologist John Hunter of the University of Birmingham, with Sgt Mick Swindells of Lancashire Constabulary, providing the first evidence by an archaeologist in a British court; Swindells had found 5 yr old Rosie McCann, of Moorheys in Oldham, in only a few hours in March 1996, after she had disappeared on 14 January 1996 - the local police had been, conversely, searching for seven weeks and had not found anything in that time, and with the generous assistance of RAF search teams; the FSAG adopted a much different searching approach to typical police methods, with archaeology, more educated guesses, and applied geophysics; the individual was part of Naval Party 8901, to train locals in civil defence in 1980; Islands Radio; the team took ground-penetrating radar and five local policemen; three years previously detectives from Devon and Cornwall Police conducted an investigation and arrested four people - three of those were Titch Jaffray, Burnerd Peck and Tony Blake; the team were conducting a nine-day search in 1997; 80-90% of murders have disposal in known areas to the murderer; Chris Johnson was a former Royal Marine; the team looked in the cemetery first, with ground-penetrating radar, which could detect up to three metres below the surface, for irregularities; Tim Cotter, from the Royal Navy; the team knew that any disused buildings would be a plausible hiding place, as nothing is often suspected; in a search site, the team found mixed, or disturbed, soil. Narrated by Robin Ellis, made with the Discovery Channel 28 July Miracle Police, including the Audrey Santo case; personnel of the Roman Catholic Diocese of Worcester; the investigator Joe Nickell; Peter Gumpel of the Congregation for the Causes of Saints; evolutionary psychologist Robin Dunbar; John Polkinghorne of the University of Cambridge; Karen Armstrong, who wrote A History of God; the Lourdes Medical Bureau; Luigi Bommarito, Archbishop from 1988 to 2002 of the Roman Catholic Archdiocese of Catania. Narrated by Piers Gibbon, directed by Alexander Marengo, made by Ideal World with the Discovery Channel 4 August Dawn of the Death Ray, about the laser and its invention in July 1960; physicist Arthur Schawlow, inventor of the laser; testing of lasers took place at Kirtland Air Force Base, New Mexico, where an aircraft was first brought down with a laser in November 1973; a laser-equipped Boeing KC-135 was operated from 1973, by the 4900th Flight Test Group, led by Col John Otten, taking off in January 1975; fighter aircraft would launch air to air missiles, with insufficient fuel, at the aircraft, and the laser would attempt to shoot the missile down; after three years, on 26 May 1983, the laser shot down its first air to air Sidewinder missile; adverse atmospheric conditions often made an airborne laser ineffective; the White Sands Missile Range in New Mexico, and Leik Myrabo of the USAF Advanced Concepts Division; the 1991 Gulf War allowed much advanced technology to be fully evaluated - and Patriot missiles had mostly missed Iraqi Scud missiles; the Directed Energy Directorate of the Air Force Research Laboratory, and its Starfire Optical Range, and physicist Robert Fugate; John V. Breakwell; the USAF ordered seven airborne attack lasers, for delivery by 2008; Major-General Don Lamberson. Narrated by Michael Bywater, directed by Chris Durlacher, produced by David Dugan, made by Windfall Films 11 August Thin Air, about climbers on Mount Everest; in the 1996, eight participants on an Everest expedition died in one day; above 17,000 ft climbers experience weight loss and sleep loss; Peter Hackett (mountaineer); Ed Viesturs from Seattle; David Breashears, who made the documentary; when he was making a film in May 1996, eight climbers died in the 1996 Mount Everest disaster; climbers fly by helicopter to 9,000 ft, then climb to base camp at 17,600 ft; pulmonologist Brownie Schoene of the University of Washington School of Medicine in Seattle; psychologist Gail Rosenbaum; chronic mountain sickness and the portable hyperbaric bag, which is pumped to 2 PSI; the Khumbu Glacier and Khumbu Icefall; Guy Cotter of Adventure Consultants; the 'death zone' is above 26,000 ft; the Lhotse western face; the team reach the South Col, known as Camp VI; the Hillary Step; pulse oximetry and brain MRI scans are taken in Seattle. Broadcast on PBS as Everest - the death zone, when narrated by Jodie Foster. British edition narrated by Piers Gibbon, directed by David Breashears, made by Nova 18 August The Ten Plagues of Egypt, about the Plagues of Egypt in the Book of Exodus; Avi Weiss, who researched the Book of Exodus; doctor John S. Marr looked at the Ipuwer Papyrus, and worked with Curtis Malloy; marine biologist JoAnn Burkholder of North Carolina State University, and how Pfiesteria piscicida could be the first plague; Richard Wassersug of Dalhousie University in Canada, and a plague of frogs; entomologist Richard Brown of Mississippi State University in Starkville, Mississippi; public health entomologist Andrew Spielman of Harvard T.H. Chan School of Public Health; Roger Breeze of Plum Island Animal Disease Center; the final plague was likely caused by Stachybotrys chartarum, which made mycotoxin. Narrated by Jenni Murray, produced by Peter Spry-Leverton, directed by Bill Eagles, made by UFA GmbH and Café Productions, with The Learning Channel
The diverse range of intrinsic activities of cyclotides also continues to hold promise for a wide range of applications in the agricultural fields against insects and nematodes, especially those from Clitoria ternatea.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.